Claudia Cicala

Claudia Cicala

Auto-generated profile, based on publicly available information

Claudia Cicala

Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CCClaudia Cicala
Claudia Cicala
EMElena Martinelli
Elena Martinelli
JMJonathan P. McNally
Jonathan P. McNally
DGDiana J. Goode
Diana J. Goode
RGRavindra Gopaul
Ravindra Gopaul
JAJames Arthos
James Arthos
Both activated and resting CD4 + T cells in mucosal tissues play important roles in the earliest phases of infection after sexual transmission of HIV-1, a process that is inefficient. HIV-1 gp120 binds to integrin α 4 β 7 (α 4 β 7 ), the gut mucosal homing receptor. We find that α 4 β 7 high CD4 + T cells are more susceptible to productive infection than are α 4 β 7 low-neg CD4 + T cells in part because this cellular subset is enriched with metabolically active CD4 + T cells. α 4 β 7 high CD4 + T cells are CCR5 high and CXCR4 low ; on these cells, α 4 β 7 appears in a complex with CD4. The specific affinity of gp120 for α 4 β 7 provides a mechanism for HIV-1 to target activated cells that are critical for efficient virus propagation and dissemination following sexual transmission.

27 January 2011 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
CCClaudia Cicala
Claudia Cicala
JAJames Arthos
James Arthos
AFAnthony S Fauci
Anthony S Fauci
It is well established that HIV-1 infection typically involves an interaction between the viral envelope protein gp120/41 and the CD4 molecule followed by a second interaction with a chemokine receptor, usually CCR5 or CXCR4. In the early stages of an HIV-1 infection CCR5 using viruses (R5 viruses) predominate. In some viral subtypes there is a propensity to switch to CXCR4 usage (X4 viruses). The receptor switch occurs in ~ 40% of the infected individuals and is associated with faster disease progression. This holds for subtypes B and D, but occurs less frequently in subtypes A and C. There are several hypotheses to explain the preferential transmission of R5 viruses and the mechanisms that lead to switching of co-receptor usage; however, there is no definitive explanation for either. One important consideration regarding transmission is that signaling by R5 gp120 may facilitate transmission of R5 viruses by inducing a permissive environment for HIV replication. In the case of sexual transmission, infection by HIV requires the virus to breach the mucosal barrier to gain access to the immune cell targets that it infects; however, the immediate events that follow HIV exposure at genital mucosal sites are not well understood. Upon transmission, the HIV quasispecies that is replicating in an infected donor contracts through a “genetic bottleneck”, and often infection results from a single infectious event. Many details surrounding this initial infection remain unresolved. In mucosal tissues, CD4+ T cells express high levels of CCR5, and a subset of these CD4+/CCR5high cells express the integrin α4β7, the gut homing receptor. CD4+/CCR5high/ α4β7high T cells are highly susceptible to infection by HIV-1 and are ideal targets for an efficient productive infection at the point of transmission. In this context we have demonstrated that the HIV-1 envelope protein gp120 binds to α4β7 on CD4+ T cells. On CD4+/CCR5high/ α4β7high T cells, α4β7 is closely associated with CD4 and CCR5. Furthermore, α4β7 is ~3 times the size of CD4 on the cell surface, that makes it a prominent receptor for an efficient virus capture. gp120-α4β7 interactions mediate the activation of the adhesion-associated integrin LFA-1. LFA-1 facilitates the formation of virological synapses and cell-to-cell spread of HIV-1. gp120 binding to α4β7 is mediated by a tripeptide located in the V1/V2 domain of gp120. Of note, the V1/V2 domain of gp120 has been linked to variations in transmission fitness among viral isolates raising the intriguing possibility that gp120-α4β7 interactions may be linked to transmission fitness. Although many details remain unresolved, we hypothesize that gp120-α4β7 interactions play an important role in the very early events following sexual transmission of HIV and may have important implication in the design of vaccine strategies for the prevention of acquisition of HIV infection

27 October 2013 in Nature Immunology
Verified
Journal Article
Open access
PDF file
KJKatija Jelicic
Katija Jelicic
RCRaffaello Cimbro
Raffaello Cimbro
FNFatima Nawaz
Fatima Nawaz
DHDa Wei Huang
Da Wei Huang
XZXin Zheng
Xin Zheng
AFAnthony S Fauci
Anthony S Fauci
Antibody responses are impaired during HIV-1 infection. Cicala and colleagues show that the HIV-1 glycoprotein gp120 directly impairs B cell function by promoting expression of TGF-β and the inhibitory receptor FcRL4. The humoral immune response after acute infection with HIV-1 is delayed and ineffective. The HIV-1 envelope protein gp120 binds to and signals through integrin α4β7 on T cells. We found that gp120 also bound to and signaled through α4β7 on naive B cells, which resulted in an abortive proliferative response. In primary B cells, signaling by gp120 through α4β7 resulted in increased expression of the immunosuppressive cytokine TGF-β1 and FcRL4, an inhibitory receptor expressed on B cells. Coculture of B cells with HIV-1-infected autologous CD4+ T cells also increased the expression of FcRL4 by B cells. Our findings indicated that in addition to mediating chronic activation of the immune system, viral proteins contributed directly to HIV-1-associated B cell dysfunction. Our studies identify a mechanism whereby the virus may subvert the early HIV-1-specific humoral immune response.

27 February 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CCClaudia Cicala
Claudia Cicala
JAJames Arthos
James Arthos
EMElena Martinelli
Elena Martinelli
NCNina Censoplano
Nina Censoplano
CCCatherine C. Cruz
Catherine C. Cruz
AFAnthony S. Fauci
Anthony S. Fauci
HIV envelope binds to and signals through its primary cellular receptor, CD4, and through a coreceptor, either CC chemokine receptor 5 (CCR5) or CXC chemokine receptor 4 (CXCR4). Here, we evaluate the response of peripheral blood mononuclear cells to a panel of genetically diverse R5 and X4 envelope proteins. Modulation of gene expression was evaluated by using oligonucleotide microarrays. Activation of transcription factors was evaluated by using an array of oligonucleotides encoding transcription factor binding sites. Responses were strongly influenced by coreceptor specificity. Treatment of cells from CCR5Δ32 homozygous donors with glycoprotein (gp)120 derived from an R5 virus demonstrated that the majority of responses elicited by R5 envelopes required engagement of CCR5. R5 envelopes, to a greater extent than X4 envelopes, induced the expression of genes belonging to mitogen-activated protein kinase signal transduction pathways and genes regulating the cell cycle. A number of genes induced by R5, but not X4, envelopes were also up-regulated in the resting CD4+T cell population of HIV-infected individuals. These results suggest that R5 envelope facilitates replication of HIV in the pool of resting CD4+T cells. Additionally, signaling by R5 gp120 may facilitate the transmission of R5 viruses by inducing a permissive environment for HIV replication.

6 September 2019 in Science
Verified
Journal Article
Closed access
PDF file
NINami Iwamoto
Nami Iwamoto
RMRosemarie D. Mason
Rosemarie D. Mason
KSKaimei Song
Kaimei Song
JGJason Gorman
Jason Gorman
HWHugh C. Welles
Hugh C. Welles
MRMario Roederer
Mario Roederer
An antibody is not the antidote: An HIV therapeutic that would give long-term remission without sustained antiretroviral therapy (ART) is a long-term goal. Byrareddy et al. [ Science 354 , 197 (2016)] reported that treating simian immunodeficiency virus (SIV)–positive macaques with an antibody against integrin α 4 β 7 during and after ART results in sustained virologic control after stopping all treatment. Three studies in this issue question the reproducibility of that result. Di Mascio et al. sequenced the virus used in the 2016 study and found that it was a variant with a stop codon in the nef gene rather than a wild-type virus. Abbink et al. used the same antibody for α 4 β 7 as before but tested control of a more commonly used pathogenic virus. Iwamato et al. used the same nef -stop virus as in the earlier paper but combined the antibody against the integrin with an antibody against the SIV envelope glycoprotein, which also blocks viral binding of the integrin. None of these three new studies found that treating with the antibody had any effect on virologic control after stopping ART treatment. Science , this issue p. 1025 , p. 1029 , p. 1033

10 March 2023 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SVSinmanus Vimonpatranon
Sinmanus Vimonpatranon
LGLivia R Goes
Livia R Goes
ACAmanda Chan
Amanda Chan
ILIsabella Licavoli
Isabella Licavoli
JMJordan McMurry
Jordan McMurry
CCClaudia Cicala
Claudia Cicala
CD4+ tissue resident memory T cells (TRMs) are implicated in the formation of persistent HIV reservoirs that are established during the very early stages of infection. The tissue-specific factors that direct T cells to establish tissue residency are not well defined, nor are the factors that establish viral latency. We report that costimulation via MAdCAM-1 and retinoic acid (RA), two constituents of gut tissues, together with TGF-β, promote the differentiation of CD4+ T cells into a distinct subset α4β7+CD69+CD103+ TRM-like cells. Among the costimulatory ligands we evaluated, MAdCAM-1 was unique in its capacity to upregulate both CCR5 and CCR9. MAdCAM-1 costimulation rendered cells susceptible to HIV infection. Differentiation of TRM-like cells was reduced by MAdCAM-1 antagonists developed to treat inflammatory bowel diseases. These finding provide a framework to better understand the contribution of CD4+ TRMs to persistent viral reservoirs and HIV pathogenesis.